British drugmaker Emergex suggests a A new generation of Covid-19 vaccines: Apply to the skin as a stickyand wants to stimulate a response directly with T cells (a component of the immune system).

You are Human clinical trials Starting January 3, 2022, in Lausanne (Switzerland), it will have 26 volunteers, in the first phase, informs the pharmacist. Even June 2022, the company expects to have the first results Tests at a lower and higher dose. However, the vaccine may only be available on the market in 2025.

The vaccine consists of an adhesive placed on the skin with fine needles that inject tiny gold particles covered with bits of virus proteins.

The idea is It directly produces T cells capable of killing infected human cells With the SARS-CoV-2 coronavirus, it is quickly removed from the body – with no chance for the virus to multiply or cause disease. The advantage is that T cells can attack different types of coronavirus.

The remaining vaccines, both mRNA-based and adenovirus-based, Stimulates an initial response with antibodies that block the infected cells, which will subsequently be eliminated by T cells (whose production is also triggered by existing vaccines).

Danny Altman, Professor of Immunology at Imperial College London, continues to advocate the ability of existing vaccines to stimulate the production of neutralizing antibodies. The Guardian has argued that Emergex vaccine may be important if used as a supplement, in the vaccine mix-up scheme in the same vaccine scheme.